M Markman

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi Chemotherapeutic management of recurrent/metastatic uterine carcinosarcomas (malignant mixed mullerian tumors): time for a re-appraisal?
    Maurie Markman
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Mail Box 121, 77030, Houston, Texas 77030, USA
    J Cancer Res Clin Oncol 130:645-8. 2004
  2. ncbi Examples of the marked variability in the relationship between the serum CA-125 antigen level and cancer-related symptoms in ovarian cancer
    Maurie Markman
    Department of Hematology Medical Oncology and Gynecology Obstetrics, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 93:715-7. 2004
  3. ncbi Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial
    Maurie Markman
    The Cleveland Clinic Foundation, OH 44195, USA
    J Clin Oncol 21:2460-5. 2003
  4. ncbi Toxicity associated with carboplatin/paclitaxel/Irinotecan use in advanced ovarian cancer: preliminary analysis
    Maurie Markman
    Cleveland Clinic Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Oncology (Williston Park) 17:34-5. 2003
  5. ncbi Limitations to the use of the CA-125 antigen level in ovarian cancer
    Maurie Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Oncol Rep 5:263-4. 2003
  6. ncbi Intraperitoneal antineoplastic drug delivery: rationale and results
    Maurie Markman
    Cleveland Clinic Taussig Cancer Center, and the Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, OH 44195, USA
    Lancet Oncol 4:277-83. 2003
  7. ncbi Supportive care
    Maurie Markman
    Cleveland Clinic Taussig Cancer Center, Department of Hematology Medical Oncology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Cancer Chemother Biol Response Modif 20:627-32. 2002
  8. ncbi Optimizing primary chemotherapy in ovarian cancer
    Maurie Markman
    Department of Hematology Medical Oncology R 35, Cleveland Clinic Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Hematol Oncol Clin North Am 17:957-68, viii. 2003
  9. ncbi Managing taxane toxicities
    Maurie Markman
    Department of Hematology Medical Oncology R35, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Support Care Cancer 11:144-7. 2003
  10. ncbi Second-line chemotherapy of epithelial ovarian cancer
    Maurie Markmon
    Department of Hematology Medical Oncology, The Cleveland Clinic Cancer Center, The Cleveland Clinic Foundation, OH 44195, USA
    Expert Rev Anticancer Ther 3:31-6. 2003

Detail Information

Publications113 found, 100 shown here

  1. ncbi Chemotherapeutic management of recurrent/metastatic uterine carcinosarcomas (malignant mixed mullerian tumors): time for a re-appraisal?
    Maurie Markman
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Mail Box 121, 77030, Houston, Texas 77030, USA
    J Cancer Res Clin Oncol 130:645-8. 2004
    ....
  2. ncbi Examples of the marked variability in the relationship between the serum CA-125 antigen level and cancer-related symptoms in ovarian cancer
    Maurie Markman
    Department of Hematology Medical Oncology and Gynecology Obstetrics, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 93:715-7. 2004
    ..g., development of cancer-related symptoms) in individual patients remains poorly defined...
  3. ncbi Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial
    Maurie Markman
    The Cleveland Clinic Foundation, OH 44195, USA
    J Clin Oncol 21:2460-5. 2003
    ....
  4. ncbi Toxicity associated with carboplatin/paclitaxel/Irinotecan use in advanced ovarian cancer: preliminary analysis
    Maurie Markman
    Cleveland Clinic Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Oncology (Williston Park) 17:34-5. 2003
    ..Randomized trials will be required to define a possible role for this three-drug combination chemotherapy regimen in the standard management of advanced ovarian cancer...
  5. ncbi Limitations to the use of the CA-125 antigen level in ovarian cancer
    Maurie Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Oncol Rep 5:263-4. 2003
  6. ncbi Intraperitoneal antineoplastic drug delivery: rationale and results
    Maurie Markman
    Cleveland Clinic Taussig Cancer Center, and the Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, OH 44195, USA
    Lancet Oncol 4:277-83. 2003
    ....
  7. ncbi Supportive care
    Maurie Markman
    Cleveland Clinic Taussig Cancer Center, Department of Hematology Medical Oncology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Cancer Chemother Biol Response Modif 20:627-32. 2002
  8. ncbi Optimizing primary chemotherapy in ovarian cancer
    Maurie Markman
    Department of Hematology Medical Oncology R 35, Cleveland Clinic Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Hematol Oncol Clin North Am 17:957-68, viii. 2003
    ....
  9. ncbi Managing taxane toxicities
    Maurie Markman
    Department of Hematology Medical Oncology R35, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Support Care Cancer 11:144-7. 2003
    ..g., for hypersensitivity reactions, bone marrow suppression) the taxanes have a favorable side effect profile, and it is currently uncommon for treatment to be discontinued because of the development of excessive toxicity...
  10. ncbi Second-line chemotherapy of epithelial ovarian cancer
    Maurie Markmon
    Department of Hematology Medical Oncology, The Cleveland Clinic Cancer Center, The Cleveland Clinic Foundation, OH 44195, USA
    Expert Rev Anticancer Ther 3:31-6. 2003
    ....
  11. ncbi Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity
    Maurie Markman
    Department of Hematology Medical Oncology R 35, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    J Clin Oncol 21:4611-4. 2003
    ..Carboplatin-associated hypersensitivity is increasingly recognized as a potentially serious toxicity when this agent is administered for more than six total cycles...
  12. ncbi Progress in preventing chemotherapy-induced nausea and vomiting
    Maurie Markman
    The Cleveland Clinic Taussig Cancer Center, The Cleveland Clinic Foundation, Ohio 44195, USA
    Cleve Clin J Med 69:609-10, 612, 615-7. 2002
    ..Prevention and treatment of the delayed and anticipatory forms of chemotherapy-induced emesis remain a challenge...
  13. ncbi Intraperitoneal chemotherapy in the management of malignant disease
    M Markman
    Cleveland Clinic Taussig Cancer Center R30, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    Expert Rev Anticancer Ther 1:142-8. 2001
    ....
  14. ncbi Role of chemotherapy in the management of ovarian cancer
    Maurie Markman
    Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    Expert Rev Anticancer Ther 2:90-6. 2002
    ..Further complicating the decision-making process in choosing an 'optimal' second-line regimen is a serious paucity of randomized trials in this clinical setting...
  15. ncbi Second-line therapy of ovarian cancer with Paclitaxel administered by both the intravenous and intraperitoneal routes: rationale and case reports
    Maurie Markman
    Cleveland Clinic Taussig Cancer Center, Department of Gynecology Obstetrics, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Gynecol Oncol 86:95-8. 2002
    ....
  16. ncbi Potential conflict between fundamental ethical principles and requirements of the oncology drug approval process: ethical conflict in drug approval
    Maurie Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Cancer 98:215-8. 2003
  17. ncbi Management of toxicities associated with the administration of taxanes
    Maurie Markman
    Department of Hematology Medical Oncology R35, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Expert Opin Drug Saf 2:141-6. 2003
    ..In general, the side effects of the taxanes are manageable, and few patients discontinue treatment due to excessive toxicity...
  18. ncbi Informing patients with cancer of "new findings" that may influence their willingness to participate in research studies
    Maurie Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Cancer 98:885-7. 2003
  19. ncbi Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy
    Jonathan Markman
    Department of Hematology Medical Oncology, Gynecology Obstetrics, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 92:592-5. 2004
    ..The prophylactic oral administration of a broad-spectrum antibiotic (e.g., ciprofloxicin) in the presence of grade 4 neutropenia appears to be an effective strategy to minimize the risk of subsequent febrile events...
  20. ncbi Ethical conflict in providing informed consent for clinical trials: a problematic example from the gynecologic cancer research community
    Maurie Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Oncologist 9:3-7. 2004
    ....
  21. ncbi Genetic discrimination arising from cancer risk assessments: a societal dilemma
    Maurie Markman
    Department of Hematology Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 71:12, 15-8. 2004
  22. ncbi The needs of science vs the needs of patients: ethical concerns in cancer clinical trials
    Maurie Markman
    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 70:1008-9, 1013-4, 1016. 2003
  23. ncbi Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum
    Maurie Markman
    Departments of Hematology Medical Oncology and Gynecology Obstetrics, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Gynecol Oncol 91:573-6. 2003
    ..We wished to evaluate the biological and clinical activity of docetaxel in a patient population with well-characterized platinum and paclitaxel-refractory ovarian cancer...
  24. ncbi Consolidation therapy revisited: intravenous chemotherapy
    M Markman
    The Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Int J Gynecol Cancer 13:204-7. 2003
    ..31). Further exploration of consolidation/maintenance therapy in the management of ovarian cancer is indicated, focusing on agents that are easy to administer (eg, oral) and that result in limited cumulative toxicity...
  25. ncbi Toxicities of the platinum antineoplastic agents
    Maurie Markman
    Department of Hematology Medical Oncology R 35, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio, USA
    Expert Opin Drug Saf 2:597-607. 2003
    ..Furthermore, with appropriate dose modifications, the large majority of patients who may benefit from this class of cytotoxic pharmaceutical drugs will be able to complete a planned therapeutic programme...
  26. ncbi Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions
    Maurie Markman
    Department of Hematology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    J Cancer Res Clin Oncol 130:25-8. 2004
    ..We wished to determine if a novel multi-pronged approach to re-treating patients with a high risk for this potentially serious side effect could permit the safe delivery of this class of cytotoxic drugs...
  27. ncbi Consolidation/maintenance chemotherapy for ovarian cancer
    Maurie Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Oncol Rep 5:454-8. 2003
    ..Whether this strategy will improve overall survival in this clinical setting remains uncertain...
  28. ncbi Surgical staging of cancer: impact on prognosis and potential for bias in clinical trials
    Maurie Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Oncol Rep 5:437-8. 2003
  29. ncbi Phase 2 trial of interferon-beta as second-line treatment of ovarian cancer, fallopian tube cancer, or primary carcinoma of the peritoneum
    Maurie Markman
    Cleveland Clinic Taussig Cancer Center, and the Departments of Hematology Medical Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Oncology 66:343-6. 2004
    ..The protocol was designed to examine the biological effects and clinical activity of interferon-beta in patients with platinum/taxane-resistant ovarian cancer...
  30. ncbi Supportive care
    Maurie Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, OH 44195, USA
    Cancer Chemother Biol Response Modif 21:709-16. 2003
  31. ncbi Does palliative chemotherapy palliate?
    Maurie Markman
    The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Support Oncol 1:65-7. 2003
  32. ncbi Assessing cancer clinical trials: will your patient benefit from a 'breakthrough'?
    Maurie Markman
    Taussing Cancer Center and Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 69:368-9, 375-6. 2002
    ..Physicians familiar with the long and complicated process of oncologic clinical trials are in the best position to assess the potential for clinical benefit from a new antineoplastic therapy...
  33. ncbi Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer
    Maurie Markman
    Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA
    J Clin Oncol 20:2365-9. 2002
    ..We wished to critically examine the level of activity of weekly paclitaxel in a patient population with well-characterized platinum/paclitaxel-resistant (3-week schedule) ovarian cancer...
  34. ncbi Phase I trial of paclitaxel plus megestrol acetate in patients with paclitaxel-refractory ovarian cancer
    M Markman
    The Cleveland Clinic Taussig Cancer Center, and Department of Gynecology Obstetrics, The Cleveland Clinic Foundation, Ohio 44195, USA
    Clin Cancer Res 6:4201-4. 2000
    ....
  35. ncbi Treatment of ovarian cancers not of epithelial origin
    M Markman
    Department of Hematology Medical Oncology, Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 67:839-42. 2000
    ....
  36. ncbi Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked ovarian cancer
    M Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Crit Rev Oncol Hematol 38:171-5. 2001
    ..However, for several reasons, additional investigative efforts are required to convince oncologists the time, effort and potential toxicity of intraperitoneal therapy justify its routine use as initial therapy of this malignancy...
  37. ncbi Regional delivery of anticancer drugs: current applications
    M Markman
    Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, USA
    Cleve Clin J Med 67:584-6. 2000
    ..However, whether it increases the cure rate remains controversial, and it is costly because of the need to surgically implant infusion devices...
  38. ncbi The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy
    M Markman
    Gynecologic Cancer Program, Cleveland Clinic Taussig Cancer Center, OH 44195, USA
    Gynecol Oncol 78:43-6. 2000
    ..The purpose of this study was to develop a cost-effective prophylactic antiemetic regimen for the prevention of carboplatin-induced emesis...
  39. ncbi Experience with prophylactic oral ciprofloxacin in gynecological cancer patients developing severe chemotherapy-induced neutropenia
    M Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Taussig Cancer Center, Ohio 44195, USA
    J Cancer Res Clin Oncol 126:298-300. 2000
    ....
  40. ncbi Intraperitoneal drug delivery of antineoplastics
    M Markman
    The Cleveland Clinic Taussig Cancer Center, Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Ohio 44195, USA
    Drugs 61:1057-65. 2001
    ....
  41. ncbi Declining CA-125 in an ovarian cancer patient with progression of measurable disease: a rational hypothesis for discordant results
    M Markman
    Cleveland Clinic Taussig Cancer Center, Department of Gynecology Obstetrics, Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Ohio 44195, USA
    Gynecol Oncol 77:321-2. 2000
    ....
  42. ncbi Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies
    M Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Ohio 44195, USA
    J Cancer Res Clin Oncol 127:55-8. 2001
    ..We conclude that while neurotoxicity is common following the use of this regimen, significant neurological dysfunction (> or = grade 2) is relatively infrequent...
  43. ncbi Second-line treatment of ovarian cancer with single-agent gemcitabine
    Maurie Markman
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Semin Oncol 29:9-10. 2002
    ....
  44. ncbi Role of intraperitoneal chemotherapy in the front-line setting
    Maurie Markman
    Cleveland Clinic Taussig Cancer Center and the Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Oncol 21:145s-148s. 2003
    ..Despite these facts, an ultimate role for regional drug delivery as initial treatment of ovarian cancer will require additional trials to define how to optimize the use of this unique therapeutic strategy...
  45. ncbi Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum
    M Markman
    Gynecologic Cancer Program, The Cleveland Clinic Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Oncol 19:1901-5. 2001
    ..Because docetaxel is an active agent in platinum-resistant ovarian cancer, it is relevant to evaluate both the toxicity and efficacy of the combination of carboplatin and docetaxel in this clinical setting...
  46. ncbi Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy
    K M Zanotti
    Department of Obstetrics and Gynecology, The Cleveland Clinic Foundation, Cleveland, Ohio, 44195, USA
    Gynecol Oncol 79:211-5. 2000
    ....
  47. ncbi Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens
    M Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, OH 44195, USA
    J Clin Oncol 16:1849-51. 1998
    ..To test the hypothesis that prolonged infusion of paclitaxel (96 hours) might overcome resistance to shorter infusion schedules (3 or 24 hours) in ovarian cancer...
  48. ncbi An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions
    M Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Ohio 44195, USA
    J Cancer Res Clin Oncol 125:427-9. 1999
    ....
  49. ncbi Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy
    Margaret R Markman
    The Cleveland Clinic Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Gynecol Oncol 85:435-7. 2002
    ..There are extremely limited data available in the general oncology or gynecologic cancer literature to document the effectiveness of antiemetic therapy over multiple courses of cytotoxic chemotherapy...
  50. ncbi Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers
    Maurie Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 95:109-13. 2004
    ..The availability of oral topotecan permits the exploration of the clinical utility of prolonged treatment programs employing this drug...
  51. ncbi Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials
    Maurie Markman
    Department of Hematology Medical Oncology and Gynecology Obstetrics, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 93:699-701. 2004
    ..There are very limited data in the oncology literature regarding the survival of women with both platinum and taxane-refractory ovarian cancer...
  52. ncbi Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy
    K M Zanotti
    Cleveland Clinic Foundation, Cleveland, OH 44012, USA
    J Clin Oncol 19:3126-9. 2001
    ..Presently, there is no reliable way to predict which patients may be at risk for this potentially severe adverse reaction. We developed a skin-test protocol to identify patients at high risk for HR to carboplatin chemotherapy...
  53. ncbi Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecol
    M Markman
    Cleveland Clinic Taussig Cancer Center, Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH, USA
    J Clin Oncol 19:1001-7. 2001
    ..However, the results provide direction for further clinical investigation in small-volume ovarian cancer...
  54. ncbi Clinical features of hypersensitivity reactions to carboplatin
    M Markman
    Cleveland Clinic Cancer Center and Department of Gynecology Obstetrics, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Oncol 17:1141. 1999
    ..To characterize the clinical features of carboplatin-associated hypersensitivity reactions...
  55. ncbi Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors
    M Markman
    The Cleveland Clinic Cancer Center, and the Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, OH 44195, USA
    J Clin Oncol 16:3483-5. 1998
    ..To examine the safety of administering paclitaxel to patients with preexisting significant cardiac risk factors...
  56. ncbi Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma
    D M Kushner
    Department of Gynecology and Obstetrics, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland Ohio 44195, USA
    Gynecol Oncol 78:221-7. 2000
    ..To our knowledge, the current study is the first to evaluate adjuvant ifosfamide in completely resected uterine sarcomas...
  57. ncbi Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers
    Pedro F Escobar
    Department of Gynecology Obstetrics, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 92:192-6. 2004
    ....
  58. ncbi Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancer
    M Markman
    Cleveland Clinic Taussig Cancer Center and the Department of Gynecology Obstetrics and Hematology Medical Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Gynecol Oncol 73:422-3. 1999
    ..Endometrial cancer should be added to the list of malignancies for which platinum and/or paclitaxel are considered as second-line treatment options in patients previously responding to the agents...
  59. ncbi Prolonged symptom-free survival in a patient with persistent primary peritoneal carcinoma and a rising CA-125: a note of caution
    M Markman
    Cleveland Clinic Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Gynecol Oncol 81:509-11. 2001
    ..CONCLUSION: This case emphasizes that caution must be exercised when electing to initiate second-line treatment solely on the basis of an abnormal tumor antigen level...
  60. ncbi Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: a Gynecologic Oncology Group study
    M Markman
    The Cleveland Clinic Cancer Center and Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Gynecol Oncol 80:359-63. 2001
    ..g., 3-h infusional paclitaxel)...
  61. ncbi Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial
    M Markman
    Department of Hematology Medical Oncology, Cleveland Clinic Cancer Center, Cleveland Clinic Foundation, Ohio 44195, USA
    Gynecol Oncol 69:226-9. 1998
    ....
  62. ncbi Prevention and management of antineoplastic-induced hypersensitivity reactions
    K M Zanotti
    Department of Obstetrics and Gynecology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Drug Saf 24:767-79. 2001
    ..As re-treatment may have serious consequences, careful consideration of the risks and benefits of these strategies is imperative when deciding among these options...
  63. ncbi A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers
    Maurie Markman
    Department of Gynecology Obstetrics, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Cancer Res Clin Oncol 131:26-30. 2005
    ..Optimal management of patients with advanced ovarian or primary peritoneal cancers who have received, and achieved an excellent response to, neoadjuvant chemotherapy remains undefined...
  64. ncbi Potential clinical utility of CA-125 in responsive but persistent large-volume ovarian cancer following platinum-based chemotherapy
    M Markman
    Cleveland Clinic Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Gynecol Oncol 83:593-5. 2001
    ..Despite the demonstrated clinical utility of the serum CA-125 antigen level in ovarian cancer, controversy exists regarding interpretation of "discordant" results between changes in this tumor marker and measurable disease masses...
  65. doi Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients
    Amanda Nickles Fader
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Gynecol Oncol 109:33-8. 2008
    ..Elderly cancer patients are less likely to tolerate chemotherapy. We sought to compare the toxicity profiles and outcomes of elderly ovarian cancer patients treated with standard versus reduced-dose i.v. carboplatin/paclitaxel...
  66. ncbi Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design
    Maurie Markman
    From the Department of Hematology Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH, USA
    J Clin Oncol 22:3120-5. 2004
    ..Limited information is available regarding the influence of the duration of a prior response on the length of a subsequent response to platinum chemotherapy in recurrent ovarian cancer...
  67. ncbi The genetics, screening, and treatment of epithelial ovarian cancer: an update
    M Markman
    Department of Hematology and Medical Oncology, Cleveland Clinic, OH 44195, USA
    Cleve Clin J Med 67:294-8. 2000
    ..The development of newer cytotoxic drugs and alternative routes of administering chemotherapy offers hope of improved survival for women with advanced ovarian cancer...
  68. ncbi Chronic administration of single-agent paclitaxel in gynecologic malignancies
    J Rohl
    Department of Gynecology and Obstetrics, Cleveland Clinic Foundation and Taussig Cancer Center, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Gynecol Oncol 81:201-5. 2001
    ..CONCLUSION: Prolonged delivery of paclitaxel for >15 consecutive cycles can be safely administered to carefully selected patients with persistent or recurrent advanced gynecologic cancers...
  69. ncbi Epidural spinal cord compression in cancer patients: diagnosis and management
    H A Daw
    Department of Hematology and Oncology, Cleveland Clinic, USA
    Cleve Clin J Med 67:497, 501-4. 2000
    ..Since the key prognostic factor is the neurologic status at the time of presentation, and since early complaints are often nonspecific, a high index of suspicion is needed to diagnose this complication early...
  70. ncbi Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, A81, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Gynecol Oncol 104:114-9. 2007
    ....
  71. ncbi The management of recurrent ovarian cancer
    Ronald M Bukowski
    The Cleveland Clinic Foundation Taussig Cancer Center, Cleveland Clinic Foundation Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA
    Semin Oncol 34:S1-15. 2007
  72. ncbi Can we do a better job preventing clinically-relevant peripheral neuropathy resulting from carboplatin/paclitaxel chemotherapy?
    Maurie Markman
    The Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Cancer Invest 22:471-3. 2004
    ....
  73. ncbi Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma
    Chad M Michener
    Departments of Obstetrics Gynecology and Hematology Medical Oncology, The Cleveland Clinic Foundation, 9500, Euclid Avenue, Desk A81, Cleveland, OH, 44195, USA
    J Cancer Res Clin Oncol 131:581-4. 2005
    ..To evaluate the efficacy and safety of the combination of carboplatin plus paclitaxel in patients with advanced, metastatic and recurrent endometrial cancer...
  74. ncbi Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers
    Robert J Kim
    Department of Gynecology Obstetrics, Gynecologic Oncology Program, Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A81, Cleveland, OH 44195, USA
    Gynecol Oncol 97:374-8. 2005
    ..To characterize the incidence of skin toxicity of pegylated liposomal doxorubicin (PLD) administered at a lower dose (40 mg/m(2)) in the treatment of advanced gynecologic malignancies...
  75. ncbi Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum
    Maurie Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Gynecol Oncol 94:404-8. 2004
    ..We wished to confirm or refute this observation in a patient population with well-characterized platinum-resistant disease...
  76. ncbi Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, and MetroHealth Medical Center, Cleveland, OH, USA
    Gynecol Oncol 102:236-9. 2006
    ..A phase I study was conducted in previously treated ovarian or peritoneal carcinoma to determine the tolerability (maximum number of days) of sequential oral topotecan and oral etoposide...
  77. ncbi Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies
    Denise Uyar
    Department of Gynecology Obstetrics and Hematology Medical Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Gynecol Oncol 94:147-51. 2004
    ..While PLD has been shown to be less cardiotoxic than doxorubicin, the safety of prolonged administration (e.g., >or=6 cycles) of the agent remains undefined...
  78. ncbi Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer
    Maurie Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 93:390-3. 2004
    ..Unfortunately, the clinical utility of the drug in this specific setting has not been well documented...
  79. ncbi Safety issues in using complementary and alternative medicine
    Maurie Markman
    Department of Hematology Medical Oncology and Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Oncol 20:39S-41S. 2002
    ..Unfortunately, there are limited available published data regarding the potential toxicity of a variety of CAM strategies...
  80. ncbi Paclitaxel in cancer therapy
    Tarek M Mekhail
    Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Expert Opin Pharmacother 3:755-66. 2002
    ..Paclitaxel is also active against AIDS-associated Kaposi's sarcoma...
  81. ncbi Are we winning or losing the war on cancer?
    Maurie Markman
    Department of Hematology Medical Oncology, and The Cleveland Clinic Taussig Cancer Center, The Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 70:632-3. 2003
  82. ncbi Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial
    Maurie Markman
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 88:282-8. 2003
    ....
  83. ncbi Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer
    Maurie Markman
    The Cleveland Clinic Taussig Cancer Center, Department of Gynecology Obstetrics, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 90:593-6. 2003
    ..We wished to further define the level of activity of gemcitabine in women with well-characterized platinum/taxane refractory disease...
  84. ncbi Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer
    Pedro F Escobar
    Department of Gynecology Obstetrics, The Cleveland Clinic Foundation, Gynecologic Oncology Program, Cleveland, Ohio 44195, USA
    J Cancer Res Clin Oncol 129:651-4. 2003
    ..To evaluate the efficacy and toxicity of pegylated liposomal doxorubicin in patients with advanced endometrial cancer...
  85. ncbi Acanthosis nigricans with endometrial carcinoma: case report and review of the literature
    Tarek M Mekhail
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Gynecol Oncol 84:332-4. 2002
    ..Only five cases of endometrial carcinoma associated with acanthosis nigricans and/or tripe palms have been reported in the literature...
  86. ncbi Carboplatin plus paclitaxel combination chemotherapy: impact of sequence of drug administration on treatment-induced neutropenia
    Maurie Markman
    Cleveland Clinic Taussig Cancer Center and Departments of Gynecology Obstetrics and Hematology Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 91:118-22. 2003
    ....
  87. ncbi Apoptotic pathways of epothilone BMS 310705
    Denise Uyar
    The Cleveland Clinic Foundation, Experimental Therapeutics Program, Taussig Cancer Center R40, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Gynecol Oncol 91:173-8. 2003
    ..Using an early passage cell culture model derived from the ascites of a patient clinically refractory to platinum/paclitaxel therapy, we evaluated the pathway of caspase-mediated apoptosis...
  88. ncbi Activity of weekly paclitaxel in patients with advanced endometrial cancer previously treated with both a platinum agent and paclitaxel
    Maurie Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 92:180-2. 2004
    ....
  89. ncbi Unfolding the pathophysiological role of bioactive lysophospholipids
    Yan Xu
    Department of Cancer Biology, The Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, OH 44195, USA
    Curr Drug Targets Immune Endocr Metabol Disord 3:23-32. 2003
    ..It is important to further evaluate the significance of targeting these bioactive LPL receptors, their downstream signaling molecules, and/or metabolic enzymes in the treatment of cancers and other diseases...
  90. ncbi Rationale for maintenance or consolidation therapy in ovarian cancer
    Maurie Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Clin Adv Hematol Oncol 1:176-8. 2003
    ..This proof of principle study should lead to further investigation in defining an optimal maintenance or consolidation strategy for the treatment of women with advanced ovarian cancer...
  91. ncbi Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity
    Margaret Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 89:514-6. 2003
    ....
  92. ncbi The "real-life" variability of CA-125 in ovarian cancer patients
    Elisa Tso
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 103:141-4. 2006
    ..Our goal was to further understand the analytical variability of CA-125 in a conventional hospital laboratory...
  93. ncbi Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer
    John P Micha
    Gynecologic Oncology Associates, Hoag Cancer Center, 351 Hospital Road, Suite 507, Newport Beach, CA 92663, USA
    Gynecol Oncol 96:132-5. 2005
    ..12 cycles of paclitaxel consolidation in patients treated with an intensive three-drug front-line regimen of carboplatin, paclitaxel, and gemcitabine...
  94. ncbi The research misconception
    Joseph P DeMarco
    Cleveland State University, USA
    Int J Appl Philos 18:241-52. 2004
    ..Our more careful and accurate analysis of the nature of clinical trials can avoid such problems...
  95. ncbi Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma
    John P Micha
    Gynecologic Oncology Associates, Hoag Cancer Center and Women s Cancer Research Foundation, Newport Beach, CA 92663, USA
    Oncology 71:49-53. 2006
    ..Consolidation/maintenance therapy in the standard management of ovarian cancer remains controversial, primarily due to the unknown impact of this strategy on overall survival...
  96. ncbi Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study
    Jeffrey D Bloss
    Division of Gynecologic Oncology, Ellis Fischel Cancer Center, University of Missouri Health Sciences Center, Columbia, USA
    J Clin Oncol 20:1832-7. 2002
    ..This study prospectively evaluates the combination of bleomycin to this regimen in women with histologically proven advanced recurrent or persistent squamous cell carcinoma of the cervix...
  97. pmc Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Onc
    David S Alberts
    University of Arizona Cancer Center, Tucson, AZ 85724 5024, USA
    Gynecol Oncol 108:90-4. 2008
    ....
  98. doi Taxanes in the management of gynecologic malignancies
    Maurie Markman
    The University of Texas, MD Anderson Cancer Center, Department of Gynecologic Medical Oncology, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 8:219-26. 2008
    ....
  99. doi Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of prog
    David S Alberts
    Arizona Cancer Center, University of Arizona, Tucson, AZ, USA
    Gynecol Oncol 109:174-81. 2008
    ..This trial was designed to evaluate IFN-gamma 1b plus carboplatin and paclitaxel in treatment-naive ovarian cancer (OC) and primary peritoneal carcinoma (PPC) patients...
  100. ncbi Pharmaceutical management of ovarian cancer : current status
    Maurie Markman
    Department of Gynecologic Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Drugs 68:771-89. 2008
    ..Reasonable goals of therapy in women with recurrent or resistant ovarian cancer are to improve overall survival, reduce the severity (and delay the occurrence) of symptoms and optimize overall quality of life...
  101. ncbi Management of ovarian cancer. An impressive history of improvement in survival and quality of life
    Maurie Markman
    The University of Texas, M D Anderson Cancer Center, Houston 77005, USA
    Oncology (Williston Park) 20:347-54; discussion 354, 357-8, 364 passim. 2006
    ..This paper will discuss that historical background, describe the increasingly favorable impact of evolving treatment paradigms in ovarian cancer, and note future directions for clinical research in this complex disease process...